HK1221726A1 - 炎性疾病中的 結合蛋白 - Google Patents
炎性疾病中的 結合蛋白Info
- Publication number
- HK1221726A1 HK1221726A1 HK16109981.4A HK16109981A HK1221726A1 HK 1221726 A1 HK1221726 A1 HK 1221726A1 HK 16109981 A HK16109981 A HK 16109981A HK 1221726 A1 HK1221726 A1 HK 1221726A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- binding protein
- inflammatory diseases
- inflammatory
- diseases
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13183193 | 2013-09-05 | ||
PCT/EP2014/069013 WO2015032932A1 (en) | 2013-09-05 | 2014-09-05 | Il-18 binding protein (il-18bp) in inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1221726A1 true HK1221726A1 (zh) | 2017-06-09 |
Family
ID=49111035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16109981.4A HK1221726A1 (zh) | 2013-09-05 | 2016-08-22 | 炎性疾病中的 結合蛋白 |
Country Status (25)
Country | Link |
---|---|
US (3) | US10858426B2 (zh) |
EP (2) | EP3978526A1 (zh) |
JP (2) | JP6820743B2 (zh) |
KR (2) | KR102321172B1 (zh) |
CN (2) | CN115925928A (zh) |
AU (1) | AU2014317035B2 (zh) |
CA (1) | CA2922498A1 (zh) |
CL (1) | CL2016000506A1 (zh) |
CY (1) | CY1124698T1 (zh) |
DK (1) | DK3041864T3 (zh) |
ES (1) | ES2892923T3 (zh) |
HK (1) | HK1221726A1 (zh) |
HU (1) | HUE055608T2 (zh) |
IL (1) | IL244169B (zh) |
LT (1) | LT3041864T (zh) |
MX (1) | MX2016002719A (zh) |
NZ (1) | NZ717671A (zh) |
PH (1) | PH12016500425A1 (zh) |
PL (1) | PL3041864T3 (zh) |
PT (1) | PT3041864T (zh) |
RU (1) | RU2731713C2 (zh) |
SG (1) | SG11201601717VA (zh) |
SI (1) | SI3041864T1 (zh) |
UA (1) | UA125204C2 (zh) |
WO (1) | WO2015032932A1 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3041864T (lt) | 2013-09-05 | 2021-10-11 | Ab2 Bio Sa | Il-18 surišantis baltymas (il-18p) uždegiminių ligų atvejais |
WO2016139297A1 (en) | 2015-03-05 | 2016-09-09 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
GB201614455D0 (en) | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
DE102016219607A1 (de) * | 2016-10-10 | 2018-04-12 | Siemens Healthcare Gmbh | Erzeugung einer mit anatomischen Bilddaten korrelierten Ergebniskarte |
US11629183B2 (en) | 2017-12-29 | 2023-04-18 | University Of Florida Research Foundation, Inc. | Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo |
TWI679279B (zh) * | 2018-05-09 | 2019-12-11 | 臺中榮民總醫院 | 檢測成人發作型史笛兒氏症之罹病風險及預後之方法 |
JP7399118B2 (ja) * | 2018-06-19 | 2023-12-15 | シャンハイテック ユニバーシティ | ヒトインターロイキン18受容体アルファおよびベータに対するヒト抗体 |
EP3892300A4 (en) * | 2018-12-03 | 2022-12-14 | Mabprotein Co.,Ltd. | ANTIBODY RECOGNIZING A NEOEPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND ITS USE |
CN110433289A (zh) * | 2019-09-10 | 2019-11-12 | 中山大学附属口腔医院 | 用于治疗牙周致病菌感染引起的牙周膜细胞功能紊乱与牙槽骨丧失的药物 |
US20230173021A1 (en) | 2020-05-06 | 2023-06-08 | Ab2 Bio Sa | IL-18 Binding Protein (IL-18BP) In Respiratory Diseases |
GB202007404D0 (en) * | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
KR20220044057A (ko) * | 2020-09-29 | 2022-04-06 | 주식회사 에이프릴바이오 | 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도 |
WO2023286694A1 (ja) | 2021-07-13 | 2023-01-19 | 国立大学法人東海国立大学機構 | 炎症性腸疾患を治療するための医薬組成物 |
WO2023067348A1 (en) * | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
CN114236139A (zh) * | 2021-12-30 | 2022-03-25 | 苏州和锐生物科技有限公司 | 一种TNF-α生物制剂的抗体检测试剂盒、制备方法 |
WO2023166206A1 (en) | 2022-03-04 | 2023-09-07 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in the treatment of vexas |
WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
ATE190629T1 (de) | 1991-01-18 | 2000-04-15 | Amgen Inc | Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
BR9509421A (pt) | 1994-10-21 | 1997-09-30 | Innogenetics Nv | Novas sequências de genotipos de vírus de hepatite C e uso como agentes profiláticos terapêuticos e diagnósticos |
US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
EP2338515A3 (en) | 2000-02-10 | 2011-11-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
ATE506959T1 (de) * | 2000-02-21 | 2011-05-15 | Merck Serono Sa | Verwendung von il-18 inhibitoren |
SK287761B6 (en) | 2000-05-05 | 2011-09-05 | Applied Research Systems Ars Holding N. V. | Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
ES2295332T3 (es) * | 2001-01-29 | 2008-04-16 | Laboratoires Serono Sa | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de cardiopatias. |
ES2334773T3 (es) * | 2001-05-16 | 2010-03-16 | Yeda Research And Development Co. Ltd. | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. |
IL159014A0 (en) * | 2001-05-25 | 2004-05-12 | Ares Trading Sa | Use of il-18 inhibitors for treating or preventing cns injuries |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
US20080076708A1 (en) * | 2003-05-13 | 2008-03-27 | Valter Altarocca | Active Variants of the Il-18 Binding Protein and Medical Uses Thereof |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
AU2011224023C1 (en) | 2003-11-12 | 2013-08-29 | Abbvie Inc. | IL-18 binding proteins |
EP1736168A4 (en) | 2004-03-11 | 2008-07-09 | Redox Bioscience Inc | INHIBITOR OF PROSTHESIS AND PREVENTIVES OR REMEDIES FOR DISEASES. |
WO2006085983A2 (en) | 2004-07-09 | 2006-08-17 | University Of North Carolina At Chapel Hill | Viral adjuvants |
PL1793859T3 (pl) | 2004-08-20 | 2009-08-31 | Smithkline Beecham Corp | Leczenie zapalenia śluzówki jamy ustnej i jelit przez podawanie ludzkiej IL-18 |
SI2267024T1 (sl) * | 2005-06-03 | 2012-09-28 | Ares Trading Sa | Proizvodnja rekombinantnega IL-18 vezavnega proteina |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7910318B2 (en) | 2005-09-15 | 2011-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Methods of diagnosing ovarian cancer and kits therefor |
WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
US20100247538A1 (en) | 2007-05-29 | 2010-09-30 | Yale University | IL-18 and Protein Kinase R Inhibition for the Treatment of COPD |
MX2013007067A (es) | 2010-12-20 | 2013-11-01 | Medimmune Ltd | Anticuerpos anti-il-18 y sus usos. |
JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
LT3041864T (lt) | 2013-09-05 | 2021-10-11 | Ab2 Bio Sa | Il-18 surišantis baltymas (il-18p) uždegiminių ligų atvejais |
WO2016139297A1 (en) | 2015-03-05 | 2016-09-09 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
-
2014
- 2014-09-05 LT LTEPPCT/EP2014/069013T patent/LT3041864T/lt unknown
- 2014-09-05 ES ES14759210T patent/ES2892923T3/es active Active
- 2014-09-05 MX MX2016002719A patent/MX2016002719A/es unknown
- 2014-09-05 US US14/916,917 patent/US10858426B2/en active Active
- 2014-09-05 DK DK14759210.9T patent/DK3041864T3/da active
- 2014-09-05 KR KR1020167008846A patent/KR102321172B1/ko active IP Right Grant
- 2014-09-05 PL PL14759210T patent/PL3041864T3/pl unknown
- 2014-09-05 CN CN202210945119.0A patent/CN115925928A/zh active Pending
- 2014-09-05 SI SI201431879T patent/SI3041864T1/sl unknown
- 2014-09-05 KR KR1020217034984A patent/KR102512797B1/ko active IP Right Grant
- 2014-09-05 WO PCT/EP2014/069013 patent/WO2015032932A1/en active Application Filing
- 2014-09-05 EP EP21181013.0A patent/EP3978526A1/en active Pending
- 2014-09-05 CN CN201480060413.7A patent/CN105722858A/zh active Pending
- 2014-09-05 RU RU2016112596A patent/RU2731713C2/ru active
- 2014-09-05 JP JP2016539564A patent/JP6820743B2/ja active Active
- 2014-09-05 NZ NZ717671A patent/NZ717671A/en unknown
- 2014-09-05 PT PT14759210T patent/PT3041864T/pt unknown
- 2014-09-05 SG SG11201601717VA patent/SG11201601717VA/en unknown
- 2014-09-05 UA UAA201603367A patent/UA125204C2/uk unknown
- 2014-09-05 EP EP14759210.9A patent/EP3041864B1/en active Active
- 2014-09-05 HU HUE14759210A patent/HUE055608T2/hu unknown
- 2014-09-05 CA CA2922498A patent/CA2922498A1/en active Pending
- 2014-09-05 AU AU2014317035A patent/AU2014317035B2/en active Active
-
2016
- 2016-02-17 IL IL244169A patent/IL244169B/en active IP Right Grant
- 2016-03-04 PH PH12016500425A patent/PH12016500425A1/en unknown
- 2016-03-04 CL CL2016000506A patent/CL2016000506A1/es unknown
- 2016-08-22 HK HK16109981.4A patent/HK1221726A1/zh unknown
-
2019
- 2019-11-21 JP JP2019210436A patent/JP2020055821A/ja active Pending
-
2020
- 2020-05-26 US US16/883,735 patent/US11530263B2/en active Active
-
2021
- 2021-09-16 CY CY20211100816T patent/CY1124698T1/el unknown
-
2022
- 2022-11-14 US US18/054,936 patent/US20230250164A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1221726A1 (zh) | 炎性疾病中的 結合蛋白 | |
IL304738A (en) | Polypeptides with hyperglycosidic bonds | |
IL253292A (en) | IL-18 binding protein and antibodies in inflammatory diseases | |
IL240838A0 (en) | Anti-3–lag binding proteins | |
HK1225641A1 (zh) | Gitr抗原結合蛋白 | |
HK1217502A1 (zh) | 結合蛋白及其應用 | |
IL240915A0 (en) | Dual-specific binding proteins directed against tnfɑ | |
HK1213194A1 (zh) | 用於新型的結合蛋白質 | |
HK1218920A1 (zh) | 改善的 結合蛋白 | |
GB201308057D0 (en) | Protein | |
GB201401955D0 (en) | Protein | |
GB201303977D0 (en) | Binding polypeptides | |
AU2013900389A0 (en) | Il-11r binding proteins and uses thereof | |
GB201302030D0 (en) | Protein | |
GB201302031D0 (en) | Protein |